Andrew Hastie

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Ana Strezova, Javier Díez‐Domingo, Kamal Al Shawafi et al. · Open Forum Infectious Diseases · 2022 · 101 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

Céline Boutry, Andrew Hastie, Javier Díez‐Domingo et al. · Clinical Infectious Diseases · 2021 · 93 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination

Andrew Hastie, Grégory Catteau, Adaora Enemuo et al. · The Journal of Infectious Diseases · 2020 · 47 citations · Full text

Veterinary Medicine, Immunology, Immunization +16

Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .

Fabrice André, Malcolm Ranson, Emma Dean et al. · Cancer Research · 2013 · 43 citations

Medicine, Oncology, Pharmacology +15

Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors .

Udai Banerji, Malcolm Ranson, Jan H.M. Schellens et al. · Cancer Research · 2013 · 26 citations

Medicine, Oncology, Pharmacology +17